Program
sovleplenib
Also written as “HMPL-523” and “HMPL-523(300mg PO QD)”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Lymphoma · Anemia, Hemolytic, Autoimmune · Lymphoma, Non-Hodgkin · Thrombocytopenia, led by HUTCHMED.
Furthest: phase 3, since Aug 8, 202114 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| HUTCHMED | 141 open or running | phase 3since Aug 8, 2021 | Mar 19, 2014 | none ahead |
Also a collaborator on its studies: iqvia-pty-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 19, 2014First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT02105129 · 118 enrolled · Australia
- Jul 13, 2015Phase 1 study in Hematologic NeoplasmsNCT02503033 · 78 enrolled · Australia
- Aug 3, 2016Phase 1 study in Mature B-cell NeoplasmsNCT02857998 · 134 enrolled · China
- Mar 23, 2018Phase 1 study in Leukemia, Myeloid, AcuteNCT03483948 · 7 enrolled · China
- Dec 10, 2018Phase 1 study in Lymphoma, Non-HodgkinNCT03779113 · 69 enrolled · United States, Denmark, Finland and more
- May 14, 2019Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT03951623 · 45 enrolled · China
- Aug 8, 2021Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT05029635 · 272 enrolled · China
- Mar 9, 2022Early phase 1 study in Healthy SubjectNCT05318820 · 39 enrolled · China
- Aug 31, 2022Phase 3 study in Warm Antibody Autoimmune Hemolytic AnemiaNCT05535933 · 111 enrolled · China
- Oct 5, 2022Phase 1 study in RecurrenceNCT05571787 · 26 enrolled · United States
- Jan 31, 2023Phase 1 study in RecurrenceNCT05720767 · 28 enrolled · United States
- Feb 7, 2023Phase 1 study in Imumune Thrombocytopenia(ITP) Human Mass BalanceNCT05781906 · 6 enrolled · China
- Feb 13, 2024Phase 1 study in Purpura, Thrombocytopenic, IdiopathicNCT06291415 · United States, Australia, Germany and more
- Nov 26, 2025Phase 1 study in HealthyNCT07348133 · 18 enrolled · China
TargetBeta
SYK →read by rule
“Tyrosine-protein kinase SYK inhibitor”ChEMBL 37, by rule
Other programs on SYK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB3473 | Sino Biopharmaceutical | phase 3 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07348133Healthy · China | 1 | Completed | Jan 12, 2026 | 18 |
| NCT06291415Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Germany and more | 1 | Withdrawn | Apr 2026 | 0 |
| NCT05781906Imumune Thrombocytopenia(ITP) Human Mass Balance · China | 1 | Completed | Jun 1, 2023 | 6 |
| NCT05720767Recurrence · United States | 1 | Completed | Feb 5, 2023 | 28 |
| NCT05571787Recurrence · United States | 1 | Completed | Sep 22, 2022 | 26 |
| NCT05535933Warm Antibody Autoimmune Hemolytic Anemia · China | 3 | Active, not recruiting | Nov 25, 2025 | 111 |
| NCT05318820Healthy Subject · China | Early 1 | Completed | Jul 31, 2022 | 39 |
| NCT05029635Purpura, Thrombocytopenic, Idiopathic · China | 3 | Completed | May 16, 2025 | 272 |
| NCT03951623Purpura, Thrombocytopenic, Idiopathic · China | 1 | Completed | Oct 30, 2021 | 45 |
| NCT03779113Lymphoma, Non-Hodgkin · United States, Denmark, Finland and more | 1 | Terminated | Feb 26, 2025 | 69 |
| NCT03483948Leukemia, Myeloid, Acute · China | 1 | Terminated | Sep 9, 2019 | 7 |
| NCT02857998Mature B-cell Neoplasms · China | 1 | Completed | Jun 30, 2021 | 134 |
| NCT02503033Hematologic Neoplasms · Australia | 1 | UNKNOWN | Dec 2020 | 78 |
| NCT02105129Arthritis, Rheumatoid · Australia | 1 | Completed | Dec 2015 | 118 |
How it is read
Names in the registry
- “HMPL-523”, 13 entries
- “HMPL-523(300mg PO QD)”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 3 studies
- Lymphoma, 2 studies
- Anemia, Hemolytic, Autoimmune, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Thrombocytopenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.